Yescarta (axicabtagene ciloleucel)

pCPA File Number: 22285
Negotiation Status:
Under consideration for negotiation
for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy
Gilead Sciences Canada Inc.
CADTH Project Number:
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable